low-dose IL-2

Phase 2Small molecule

IIovance Biotherapeutics, Inc.

low-dose IL-2 is one of 63 small molecule programs targeting Miscarriage. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MiscarriageActive, not recruiting

MelanomaActive, not recruiting

MiscarriagePhase 1/Phase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

98 2

Imjudo

AstraZeneca

Phase 3

2 3

Deltavit

HHyundai Pharmaceutical Co., LTD.

KIMMTRAK

2 5

Peg-IFN Alfa-2b

Merck & Co.

Phase 3

1 6

Histamine Dihydrochloride

MMaxim Pharmaceuticals

Phase 3

1 7

Relatlimab+nivolumab

Bristol-Myers Squibb

Phase 3

2 8

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 9

Intron a

Merck & Co.

Preclinical

4 10

Opdualag

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Tumor Infiltrating Lymphocytes

NCT05902520

Clinical

Trials by Indication[1]

Miscarriage1 trial

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT03970954·18 enrolled

Treatment1 trial

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Completed·IIovance Biotherapeutics, Inc.·Phase 1·NCT04155710·7 enrolled

Melanoma1 trial

Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma

Completed·UUniversity of Virginia·Phase 2·NCT00928902·41 enrolled

Behcet's Disease1 trial

Low-dose IL-2 Treatment on Behcet's Disease

Completed·HHeJing·Phase 2·NCT04065672·60 enrolled

Tumor Infiltrating Lymphocytes1 trial

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Active, not recruiting·AAgonOx, Inc.·Phase 1·NCT05902520·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for low-dose IL-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — low-dose IL-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for low-dose IL-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Iovance Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIovance Biotherapeutics, Inc.

low-dose IL-2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Miscarriage1 trial

Treatment1 trial

Melanoma1 trial

Behcet's Disease1 trial

Tumor Infiltrating Lymphocytes1 trial

References

Drug Info

Quick Facts

Related News